WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report—download today for expert insights, data, and a clear view of the U.S. dredging market.→ Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

0.8500 -0.0136 (-1.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
News headline image
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
Via ACCESS Newswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For RenovoRx ↗
 
Via Benzinga
News headline image
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
RENOVORX INC (NASDAQ:RNXT) Reports Significant Q3 2025 Revenue Miss and 5% Stock Drop ↗
RenovoRx Q3 2025 earnings show a 35% revenue miss, causing a stock drop. The clinical-stage biopharma provided a 2026 growth outlook to offset cash burn. 
Via Chartmill
News headline image
RenovoRx (RNXT) Q3 2025 Earnings Call Transcript ↗
RenovoRx (RNXT) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025
Via ACCESS Newswire
News headline image
iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025
Via ACCESS Newswire
News headline image
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge ↗
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings. 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
From RenovoRx, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Friday's session ↗
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
RenovoRx Revenue Jumps 28 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
RenovoRx Inc. (NASDAQ:RNXT) Q2 2025 Earnings: Revenue Surpasses Estimates, Shares Climb on Positive Results ↗
RenovoRx (NASDAQ:RNXT) Q2 2025 revenue beats estimates at $422K, shares rise 4.8%. RenovoCath adoption grows, Phase III trial progresses. Strong cash position supports operations. 
Via Chartmill
News headline image
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
From RenovoRx, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
From RenovoRx, Inc.
Via Business Wire
News headline image
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
From RenovoRx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.